Effects of a Protease Inhibitor Camostat Mesilate on Gut Microbial Function in Patients with Irritable Bowel Syndrome: A Pilot Randomized Placebo-Controlled Study
CM modulated the fecal microbiome composition and functional potentials that are related to FKBP-type PPIase activity in IBS patients. These findings suggest that protease inhibitors may modify gut microbial function along with abnormal immunological and/or stress responses that underlie pathophysiology of IBS.
Authors
- Michiko Kano (ORCID: https://orcid.org/0000-0002-8090-7782)
- Motoyori Kanazawa (ORCID: https://orcid.org/0000-0003-1953-3336)
- Motomichi Takahashi (ORCID: https://orcid.org/0000-0003-4773-5904)
- Nariyasu Mano (ORCID: https://orcid.org/0000-0003-1679-9024)
- Shin Fukudo (ORCID: https://orcid.org/0000-0003-2265-0349)
- Kentaro Miyamoto (ORCID: https://orcid.org/0000-0001-5302-2607)
- Kyoko Inooka
- Kentaro Oka
Institutions
- Tohoku University (JP)
- Tohoku University Hospital (JP)
- Miyagi Prefectural Hospital Organization (JP)
- Taiho Pharmaceutical (Japan) (JP)
Publication Details
- Journal
- Digestion
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1159/000542758
- Citations
- 2
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.93
Funders
- Miyarisan Pharmaceutical
- Ministry of Education, Culture, Sports, Science and Technology